Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0043 dose-escalation trial in moderate-to-severe hidradenitis suppurativa
ChiCTR2500095375Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of HB0043 in hidradenitis suppurativa (HS) (3 arms), sponsored by Shandong First Medical University Affiliated Dermatology Hospital. Primary endpoint: Safety at Week 24. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
HB0043
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on ChiCTR2500095375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095375.